Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Bisphosphonates and Tetracycline: Experiment Models for Their Evaluation in Calcium-Related Disorders



Hagal Cohen, V Soloman, E Breuer, A Ornoy, N Patlas, Naomi Eidelman, G Hagele, G Golomb


Purpose. This work was aimed at synthesizing novel bisphosphonates(BPs) and examining them in comparison to clinically used BPs such as pamidronate and alendronate, and to tetracycline, in order to evaluate their potential as anticalcification and antiresorption agents. The correlation between the various models was examined in order to establishfacile experimental models for pre-screening of potential compounds.Methods. N-containing heterocyclic, novel BPs such as 2-(3-methylimidazolio) ethylidene-1,1-bisphonic acid betaine (VS-5b), 2-(2-dimethylamino-4-pyrazinio)ethylidene-1,1-bisphosphonic acid betaine (VS-6b), and 2-(2--pyridylethylthio) ethyliden-1,1-bisphosphonic acid (ISA-225), were synthesized and evaluated in comparison to clinically used BPs, in various experimental models of resorption and calcification.Results. The physicochemical properties of the novel compounds are slightly different than the BPs in clinical use; the pKa values are lower, the affinity for hydroxyapatite is lower and the solubilities of the calcium salts are higher. The anticalcification potencies of the novel compounds were high and ranked as follows: alendronate = Pamidronate >VS-6b=VS-5b=ISA-225 > tetracycline. The in vivo antiresorption activity possessed by VS-5b and VS-6b in comparison to that of the clinically employed, pamidronate, was shown to be similar and higher, respectively. Conclusions. The anticalcification activity of the novel compounds as well as that of tetracycline was lower than that of alendronate. The antiresorption activity of VS-6b was similar to that of pamidronante. A good correlation between the different models was found, enabling the facile screening of novel compounds. The activities of tetracycline and EDTA highlight the distinct behavior of a BPS as crystal poison. In addition, tetracycline was found to be a potent anticalcification agent in the ectopic calcifiction model.
Pharmaceutical Research
No. 4


bisphosphonates, bone resorption, calcification, hydroxyapatite, inhibition, tetracycline


Cohen, H. , Soloman, V. , Breuer, E. , Ornoy, A. , Patlas, N. , Eidelman, N. , Hagele, G. and Golomb, G. (1998), Bisphosphonates and Tetracycline: Experiment Models for Their Evaluation in Calcium-Related Disorders, Pharmaceutical Research (Accessed April 15, 2024)
Created December 31, 1997, Updated October 12, 2021